Oxygenta Pharmaceutical (524636) Q2 2026 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter and half-year ended September 30, 2025, and appointed a new CFO effective November 7, 2025.

• Notice of postal ballot and appointment of scrutinizer for e-voting process were approved.

Financial highlights

• Total income from operations for Q2 FY26 was ₹1,430.23 lakhs, up from ₹1,400.52 lakhs in Q2 FY25.

• Net loss for Q2 FY26 was ₹493.04 lakhs, compared to a net loss of ₹285.38 lakhs in Q2 FY25.

• Loss before tax for Q2 FY26 was ₹643.78 lakhs, higher than ₹277.33 lakhs in Q2 FY25.

• EPS (basic and diluted) for Q2 FY26 was (₹1.33) and (₹1.65), compared to (₹0.81) and (₹0.78) in Q2 FY25.

Outlook and guidance

• Company is prioritizing compliance and transparency, especially in identifying MSME creditors and improving reporting accuracy.